



Guidelines for the Management of  
**Prostate Cancer**



Guidelines for the Management of  
**Prostate Cancer**

**Full  
Version**



# Guidelines For The Management of Prostate Cancer

## Objective:

This guideline reviews the overall management (from initial presentation and diagnosis through referral, treatment and follow up) of prostate cancer in Nova Scotia. This guideline was written for an audience of *general practitioners and medical students*, not necessarily prostate cancer specialists. As such, it is a synthesis of knowledge and evidence, and reflects the practice policies of the Genitourinary Cancer Site Team in Nova Scotia (see Appendix I). A simplified discussion with flowcharts (practice pathways) will summarize the written contents.

Patients, family members and other non-health professionals are encouraged to review materials written specifically for them. The Canadian Cancer Society Information Service (1-888-939-3333 or [www.cancer.ca](http://www.cancer.ca)) is one source for this type of information.

## Preamble Note:

Practice guidelines are intended to assist health care professionals with decisions throughout the spectrum of the cancer experience. This guideline is intended to assist health care professionals to care for patients with prostate cancer.

Guidelines should never replace specific decisions for individual patients, and do not substitute for the shared decisions between any patient and doctor (or other health professional) which are unique to each circumstance. Guidelines do provide evidence-based background information, consensus-based recommendations for similar problems, and a context for each individual decision.

This guideline will be reviewed in three years from publication date or earlier if important new evidence becomes available. Current versions of this guideline will be available on the *Cancer Care Nova Scotia* website ([www.cancercare.ns.ca](http://www.cancercare.ns.ca)).

These guidelines are designed for health care professionals, working in a variety of settings. For front-line health care givers, the “Quick Reference Version” of the guidelines will be a useful reminder of assessment and treatment. This version will be useful for those who prefer to read more about the recommendations. The full evidence-based discussions of these guidelines are located in the Appendices, available on request or at the *Cancer Care Nova Scotia* website. Development of these guidelines is described in Appendix II.

## Comment on Clinical Research:

An important component of treatment decision-making for any patient is the potential for enrollment in relevant clinical research. The Genitourinary Cancer Site Team is committed to advancing patient care, through participation in clinical trials and other clinical research projects. At any point in time, there may be a clinical trial or other clinical research opportunity related to any component of this guideline. As specific trials or clinical research projects become available, eligible patients may be offered the opportunity to enroll in the relevant trial or research project. Every effort will be made to accommodate patients for clinical research participation, but there will be eligibility restrictions for each trial. Patients are encouraged to discuss clinical trials opportunities with their cancer specialist. Other researchers may also contact patients to offer participation in relevant trials. Current clinical trials are listed on the *Cancer Care Nova Scotia* website ([www.cancercare.ns.ca](http://www.cancercare.ns.ca)).

## Acknowledgements:

This guideline was written by a collaborative effort of the Genitourinary Cancer Site Team, and was sponsored by *Cancer Care Nova Scotia*. Portions of this practice guideline have been adapted from guidelines prepared by the British Columbia Cancer Agency and by the

National Comprehensive Cancer Network. The guidelines also incorporate knowledge of current evidence by the cancer experts in Nova Scotia.

For further information on this, or any other Practice Guideline, please contact the CST Co-Chairs, or members of the Guidelines Resource Team, *Cancer Care Nova Scotia* (Tel. 1-866-599-2267 or by e-mail [info@ccns.nshealth.ca](mailto:info@ccns.nshealth.ca))

---

---

## Contents:

Part	Title	Page
Part 1.	Introduction	1
Part 2.	Histology & Pathology	4
Part 3.	Diagnosis and Staging	7
Part 4.	Referral Information for the New Patient Visit	10
Part 5.	Treatment of Prostate Cancer	11
Part 6.	Follow-up	18
Part 7.	Supportive Care Issues	19
Part 8.	Practice Pathways	23

---

### Guideline Approvals:

- Genitourinary Cancer Site Team-
    - Initial date approved- *12 September 2005*
    - Revision with Community Reviewer Input- *23 January 2006*
  - Cancer Care Nova Scotia, Commissioner- *15 February 2006*
- 

### Recommended citation:

Wood L, Wilke D, Rendon R, Broadfield L, Rutledge R, Gupta R, Marsh S, and Members of the Genitourinary Cancer Site Team, Guidelines for the Management of Prostate Cancer. Genitourinary Cancer Site Team, *Cancer Care Nova Scotia*, 2005

© Crown copyright, Province of Nova Scotia, 2006.  
May be reprinted with permission from *Cancer Care Nova Scotia*  
(1-866-599-2263).


# Part 1. Introduction

## 1.1 Epidemiology


In males, prostate cancer is the most common non-cutaneous cancer diagnosed, and the second most common cause of cancer death. Age specific incidence<sup>1</sup> of prostate cancer increased steeply in men over the age of 60 (Figure 1). Age-standardized incidence<sup>1</sup> increased dramatically in the early 1990's, most likely due to improved detection through the use of the Prostate Specific Antigen (PSA) test (Figure 2). Age-standardized mortality<sup>1</sup>, however, has not changed significantly over the same time period of reporting (Figure 3).

Survival rates of men with prostate cancer<sup>1</sup> are substantially better than the other two leading cancers in men, lung cancer and colorectal cancer (Figure 4). The overall five year survival rate for prostate cancer patients in Nova Scotia was 93%. Survival for prostate cancer patients<sup>1</sup> was dependant on the stage of the cancer at diagnosis, ranging from 99% five-year survival for local malignancies to 27% for patients with distant metastases (Figure 5). Fortunately, over half of the patients (53%) were diagnosed with local disease.


Figure 1. Age-specific incidence rate for common tumour sites, males, Nova Scotia 1995-1999




**Figure 2. Trends in age-standardized incidence rates for common tumour sites, males, Nova Scotia 1971-1999**



**Figure 3. Trends in age-standardized mortality rates for common tumour sites, males, Nova Scotia 1971-1999**




**Figure 4. Five-year relative survival for common tumour sites, males, Nova Scotia 1992-1996**  
*The total number of cases (N) retained for analysis appears in parenthesis and a 95% confidence interval (|—|) is presented for each estimate.*



**Figure 5. Prostate cancer survival by extent of disease, males, Nova Scotia 1992-1996**

*The total number of cases (N) retained for analysis appears in parenthesis and a 95% confidence interval (|—|) is presented for each estimate.*



## 1.2 Risk Factors

The lifetime risk of developing prostate cancer is approximately 10% and the risk of cancer related mortality is 3%. Risk of prostate cancer is higher in males with a first degree relative with prostate cancer.

## 1.3. Presentation

Patients may present with an elevated PSA without symptoms, with an asymptomatic prostate abnormality on digital rectal examination (DRE), or with lower urinary tract symptoms. Patients with metastatic disease or locally advanced disease may present with other symptoms referable to the sites of disease involvement (i.e. bone pain, visceral or lymphatic obstruction).

## 1.4 Screening<sup>2,3,4</sup>

See appendix II (CCNS – Prostate Screening Position Statement)

### 1.4.1 Prostate Specific Antigen (PSA)

#### Reference Ranges:

Normal values for PSA increase with age, as follows<sup>5</sup>:

40-49 yrs	less than 2.5 ng/mL
50-59 yrs	less than 3.5 ng/mL
60-69 yrs	less than 4.5 ng/mL
70-79 yrs	less than 6.5 ng/mL

### 1.4.2 Sensitivity And Specificity Of PSA Testing And Role Of Free PSA In Determining Risk Of Cancer:

PSA testing sensitivity is approximately 67.5% to 80% (using 4.0 ng/mL as the upper limit of normal). If only PSA testing is used for screening, 20% to 30% of tumours will be missed. To improve sensitivity, a number of methods have been suggested, including: i) digital rectal exam (DRE) for early detection screening; ii) age-adjustment of PSA, using lower limits for younger men (see Section 1.4.1.1); and iii) PSA velocity (rate of PSA change) as a prompt for biopsy.

A PSA velocity of 0.75 ng/mL per year may indicate the presence of prostate cancer. These three methods increase the sensitivity of early detection, but also increase the number of prostate biopsies performed.

Improving the specificity of early detection should reduce the number of unnecessary biopsies. To improve specificity, other methods have been suggested, including: i) using higher PSA cut-off levels for men over 60 years old; ii) using percent-free-PSA levels; and iii) using PSA density. Prostate cancer patients have lower fractions of free PSA relative to total PSA measured. Men with elevated PSA levels, but with a ratio of free/total PSA >20% to 25% have significantly lower risk of prostate cancer found on biopsy.

#### References:

1. Saint-Jacques N, MacIntyre M, Dewar R, et al. Cancer statistics in Nova Scotia: a focus on 1995-1999. Surveillance and Epidemiology Unit, *Cancer Care Nova Scotia*; 2002
2. Berner A, Harvei S, Skjorten FJ. Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer. *Br J Urol Int*, 1999; 83 (1): 47-52
3. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer. A decision analytic view. *J Am Med Assoc*, 1994; 272 (10): 773-80.
4. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. *Ann Intern Med*, 1993; 119 (9): 914-23
5. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. *J Am Med Assoc*, 1993; 270:860-864

## Part 2. Histology & Pathology

### 2.1 Histology

The vast majority of neoplasms of the prostate are adenocarcinomas. Occasionally, other histologies (sarcoma, transitional cell carcinoma, small cell carcinoma) may be seen. Prostate adenocarcinomas are typically graded by the Gleason score<sup>1,2</sup>: scores graded in the range 2-10. Tumours may also be divided as well differentiated (typically Gleason 2-6), moderately differentiated (Gleason 7), and poorly differentiated (Gleason 8-10). Tumour grade is a strong prognostic factor in both treated (surgery or radiation) patients as well as patients where observation is elected. To note, a Gleason score should not be assigned to biopsy specimen showing prostate cancer after the patient has been placed on androgen deprivation or finasteride (Propecia®, Proscar®).

### 2.2 Pathology

#### 2.2.1 Pathologic Assessment of Prostate Biopsy:

The pathology report for needle biopsy specimens<sup>3,4</sup> should include the following information:

- A comment concerning the adequacy of the specimen
- The presence or absence of malignancy
- The histologic type
- The histologic grade (Gleason Score)
- The presence or absence of perineural/lymphatic/vascular invasion
- Extension beyond the prostatic capsule into fat, if present
- Number of cores involved and percentage of surface area of cores submitted
- The presence of high grade Prostatic Intraepithelial Neoplasia (PIN), Atypical Small Acinar Proliferation (ASAP)

#### 2.2.2 Pathological Assessment of TURP Specimens:

Reports on transurethral resected specimens should include the information required when reporting needle biopsy specimens, and in addition should include the percentage of chips showing tumour.

#### 2.2.3 Pathological Assessment of Radical Prostatectomy Specimen:

Radical prostatectomy specimen resection margins should be marked with ink and these should be sampled generously. Obvious tumours should be sampled and random sections of apparently normal prostatic tissue should be taken. Pathology reports should include the following information:

- AP, lateral, and apex to base dimensions of the prostate gland in centimeters
- The presence or absence of tumour
- The extent and location of tumour
- The histologic type
- Gleason patterns and score
- The presence of high grade PIN (prostatic intra-epithelial neoplasia)
- The presence or absence of vascular/lymphatic/perineural invasion
- The presence or absence of extraprostatic extension
- The status of the surgical margins (involved versus clear)
- Seminal vesicle invasion
- The presence or absence of nodal involvement, number of nodes examined, presence of extranodal extensions (if sampled)

**Table 2.1 Gleason Grading System For Prostatic Adenocarcinoma: Histologic Patterns<sup>2</sup>**

<b>Pattern</b>	<b>Peripheral Borders</b>	<b>Stromal Invasion</b>	<b>Appearance of Glands</b>	<b>Size of Glands</b>	<b>Architecture of Glands</b>	<b>Cytoplasm</b>
1	Circumscribed pushing expansile	Minimal	Simple, round, monotonously replicated	Medium, regular	Closely packed rounded masses	Similar to benign epithelium
2	Less circumscribed; early infiltration	Mild, with definite separation of glands by stroma	Simple, round, some variability in shape	Medium, less regular	Loosely packed rounded masses	Similar to benign epithelium
3A	Infiltration	Marked	Angular with variation in shape	Medium to large	Variable packed irregular masses	More basophilic than patterns 1 & 2
3B	Infiltration	Marked	Angular with variation in shape	Small	Variable packed irregular masses	More basophilic than patterns 1 & 2
3C	Smooth, rounded	Marked	Papillary and cribriform	Irregular	Round to elongate masses	More basophilic than patterns 1 & 2
4A	Ragged infiltration	Marked	Microacinar, papillary and cribriform	Irregular	Fused with chains and cords	Dark
4B	Ragged infiltration	Marked	Microacinar, papillary and cribriform	Irregular	Fused with chains and cords	Clear (hypernephroid)
5A	Smooth, rounded	Marked	Comedocarcinoma	Irregular	Round to elongate masses	Variable
5B	Ragged infiltration	Marked	Difficult to identify gland lumens	Irregular	Fused sheets and masses	Variable

Reprinted from: Table 7-3 from Bostwick DG: UROLOGIC SURGICAL PATHOLOGY, 1/e. p.360, © 1997 Mosby. with permission from Elsevier

**References:**

1. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Urol*, 1974; 111 (1): 58-64.
2. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M: *Urologic Pathology: The Prostate*. Philadelphia: Lea and Febiger, 1977, pp 171-197.
3. Ljung BM, Cherrie R, Kaufman JJ: Fine needle aspiration biopsy of the prostate gland: a study of 103 cases with histological followup. *J Urol*, 1986; 135 (5): 955-8.
4. Algaba F, Epstein JI, Aldape HC, et al.: Assessment of prostate carcinoma in core needle biopsy—definition of minimal criteria for the diagnosis of cancer in biopsy material. *Cancer*, 1996; 78 (2): 376-81.

## Part 3. Diagnosis and Staging

### 3.1 Diagnosis- Prostate Biopsy:

An elevated PSA or abnormal DRE may indicate increased risk of prostate cancer, but they cannot determine a diagnosis of prostate cancer. The only method to confirm the presence of prostate cancer is a prostate biopsy. Usually, a prostate biopsy is performed transrectally with ultrasound guidance. Transrectal ultrasound (TRUS) has poor ability to diagnose prostate cancer<sup>1</sup>, so a normal TRUS with abnormal DRE or elevated PSA should not be used as a criterion to avoid prostate biopsy. Prostate cancer is rarely diagnosed at the time of TURP.

#### 3.1.1 Minimum Workup At The Time Of Prostatic Biopsy:

- Full history and physical examination, PSA blood test
- Bilateral biopsy of prostate with at least eight cores sampled. Additional samples may be taken from suspicious nodules or ultrasound abnormality, where appropriate

### 3.1.2 Indications For Re-Biopsy When No Invasive Cancer Present:

- Focus of ASAP or PIN (see 2.2.1) in a man eligible for curative therapy
- Progressively rising PSA
- Suspicious nodule

### 3.2 Staging Investigations

- Serum PSA will guide selection of staging studies for newly diagnosed prostate cancer
- Laboratory investigations: hemoglobin, liver function tests, creatinine, testosterone, alkaline phosphatase
- Consider bone scan, if PSA >10 ng/mL, or if Gleason Grade  $\geq 7$ , if disease is locally advanced, or if there are symptoms suggestive of metastases<sup>2,3,6,7</sup> (such as weight loss, bone pain)
- CT or MRI<sup>4,5</sup> pelvis scans may be considered if a patient has an increased likelihood of lymph node metastases (>20%), a Gleason score  $\geq 8$ , PSA > 20 ng/mL, T3 or T4 lesion<sup>4-7</sup>.
- A pelvic lymph node dissection<sup>8,9</sup> may be performed in very selected cases

**Table 3.2.1 T (Tumour) Definitions<sup>10</sup>**

<i>Clinical:</i>	
T X	Primary tumour cannot be assessed
T 0	No evidence of a primary tumour
T1	Clinically inapparent tumour, neither palpable nor visible by imaging T1a Tumour incidental finding in 5% or less of tissue resected T1b Tumour incidental finding in more than 5% of tissue resected T1c Tumour identified by needle biopsy (e.g. because of elevated PSA)
T 2	Tumour confined within prostate (Note: tumour found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging is classified as T1c) T2a Tumour involves one-half of one lobe or less T2b Tumour involves more than one-half of one lobe, but not both lobes T2c Tumour involves both lobes
T 3	Tumour extends through prostate capsule (Note: invasion into the prostatic apex or into, but not beyond, the prostatic capsule is classified as T2) T3a Extracapsular extension (unilateral or bilateral) T3b Tumour invades seminal vesicle(s)
T 4	Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles and/or pelvic wall
<i>Pathologic (pT):</i>	
pT1	<i>There is no pathologic T1 classification</i>
pT2	Organ confined pT2a Unilateral, involving one-half of one lobe or less pT2b Unilateral, involving more than one-half of one lobe, but not both lobes pT2c Bilateral disease
pT3	Extraprostatic extension pT3a Extraprostatic extension (positive surgical margin indicated by an R1 descriptor- residual microscopic disease) pT3b Seminal vesicle invasion
pT4	Invasion of bladder, rectum

Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Manual, Sixth Edition (2002)* published by Springer-Verlag New York. (For more information, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

**Table 3.2.2 N (Node) Definitions<sup>10</sup>**

<i>Clinical:</i>	
NX	Regional lymph nodes were not assessed
N0	No metastasis to regional lymph nodes
N1	Metastasis in regional lymph node(s)
<i>Pathologic (pT):</i>	
pNX	Regional lymph nodes not sampled
pN0	No positive regional lymph nodes
pN1	Metastasis in regional lymph node(s)

**Table 3.2.3 M (Metastasis) Definitions<sup>10</sup>**

MX	Distant metastasis cannot be assessed (not evaluated by any modality)
M0	No distant metastasis
M1	Distant metastasis present
M1a	Non-regional lymph node(s)
M1b	Bone(s)
M1c	Other site(s) with or without bone disease

**Stage Groupings: TNM Subsets<sup>\*10</sup>**

Stage I	T1a	N0	M0	G1	Stage IV	T4	N0	M0	Any G
Stage II	T1a	N0	M0	G2, 3-4		Any T	N1	M0	Any G
	T1b	N0	M0	Any G		Any T	Any NM1	Any G	
	T1c	N0	M0	Any G	* Grading not generally used for staging at Capital District Health Authority				
	T1	N0	M0	Any G					
	T2	N0	M0	Any G					
Stage III	T3	N0	M0	Any G					

**References:**

- Smith JA Jr, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. *J Urol*, 1997; 157 (3): 902-6.
- Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. *J Am Med Assoc*, 1993; 269 (1): 57-60.
- Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. *Cancer Invest*, 1995; 13 (1): 31-5.
- Gerber GS, Goldberg R, Chodak GW. Local staging of prostate cancer by tumor volume, prostate-specific antigen, and transrectal ultrasound. *Urology*, 1992; 40 (4): 311-6.
- Schiebler ML, Yankaskas BC, Tempany C, et al. MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. *Am J Roentgenol*, 1992; 158 (3): 559-62; discussion 563-4.
- National Comprehensive Cancer Network Practice Guidelines in Oncology, Prostate Cancer v.1.2005. NCCN, 2005
- Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate Cancer. *J Urol*, 1995; 154(6): 2144-2148
- Oesterling JE, Brendler CB, Epstein JI, et al.: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. *J Urol*, 1987; 138 (1): 92-8.
- Daniels GF Jr, McNeal JE, Stamey TA. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. *J Urol*, 1992; 147 (3 Pt 2): 870-4.
- Prostate. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 309-316.

## Part 4. Referral Information for the New Patient Visit

A letter of referral and a pathology report documenting the cancer diagnosis are the usual minimal requirements for a referral of adult patients to a tertiary cancer center. A referral need not be delayed due to incomplete results from tests (either due to test scheduling delays or waiting time for test results).

### Local Urologist

- Refer as per usual practice within local community or health care district

### Referral to the QEII Health Sciences Centre

Referrals to the Capital Health/QEII Cancer Care Program (CCP) may be faxed to the Referrals Office at 902-473-6079 (tel. 902-473-5140 or 902-473-6098). It is preferred that referrals be accompanied by the CCP Referral Form available upon request at the above phone numbers or available for downloading at [www.cdha.nshealth.ca/physicianupdate](http://www.cdha.nshealth.ca/physicianupdate). For urgent or emergent referrals, please page the appropriate specialist on call through the QEII HSC Locating service (902-473-2220) to discuss the referral.

### Referral to the Cape Breton Cancer Centre

Referrals to the Cape Breton Cancer Centre may be directed to the referrals/booking office at 902-567-7774 (fax 902-567-7911). For urgent or emergent referrals, please page the appropriate specialist on call through the Cape Breton Regional Hospital Locating service (902-567-8000) to discuss the referral.

### Referral Information

#### Letter of Referral\*

A legible referral or consultation letter highlighting presenting signs, symptoms and pertinent findings

#### Laboratory Results\*

- a. Serum PSA (prostate specific antigen) levels- including old results\*
- b. CBC (complete blood counts)

#### Biopsy Reports\*

- a. Prostate biopsy reports
- b. TURP biopsy reports

#### Operative Reports (relevant to the cancer)\*

- a. Prostatectomy
- b. Orchiectomy
- c. Other procedures

#### Diagnostic Imaging Reports\*

- a. Transrectal Ultrasound of prostate-reports\*
- b. Bone scans (with films) \*
- c. Any relevant chest radiographs (with films)
- d. Any relevant CT scans
- e. Any other relevant diagnostic imaging

#### Other Information

- a. Any relevant consultation reports
- b. Renal function test results (if done)
- c. Relevant bloodwork: BUN, creatinine, calcium (if done)
- d. Detailed information on any previous chemotherapy or radiotherapy of current malignancy
- e. Any information on previous malignancies
- f. Information on co-existing medical conditions and allergies

\* Specific information which is necessary for proper triage of referrals

Please note: If the referring physician would like to discuss a case with a specialist, feel free to call the appropriate specialist (Radiation Oncology, Medical Oncology, or Urology, by calling 902-473-2222- ask for the specialist on call or a specific physician at this number). If any tests or reports are pending, the date of the procedure, and the location of the procedure should be noted, so that the reports may be obtained when available. Send in the referral while awaiting these results, to facilitate a timely appointment for your patient.

## Part 5. Treatment

*Note: For optimal patient care, psychosocial management is integrated with medical/surgical management of the disease and symptoms.*

### 5.1 Curative Treatment Options By Risk

#### Category:

Pretreatment PSA<sup>1-8</sup>, grade<sup>9-13</sup> and clinical stage are prognostic factors for outcome following surgery<sup>14-16</sup>, radiotherapy<sup>17-21</sup>, expectant management<sup>22-25</sup> (See Appendix III for principles of expectant management) or observation<sup>26,27</sup> (See Appendix IV for principles of observation) for non-metastatic disease. Various prognostic schemes combining different categories of these factors have been proposed<sup>28-31</sup> and, in general, these schemes stratify patients into low, intermediate and high risk categories. Low risk patients have a high chance of disease control with single modality therapy (or expectant management in selected patients); high risk patients have a high chance of systemic failure with localized treatment modalities and should be considered for adjuvant therapy. Treatment of intermediate risk patients is controversial.

### 5.2 Definition Of Risk Categories With Treatment Options<sup>32</sup>:

#### 5.2.1 Low Risk

T1-T2a  
**and**  
Low PSA (< 10ng/mL)  
**and**  
Low Gleason Grade ( $\leq 6$ ):

#### Treatment Options:

Patients may choose one of these options in discussion with their doctor<sup>13,33</sup>

- Radical prostatectomy<sup>14,16,34-38</sup> (see Appendix V)
- External beam radiotherapy alone<sup>38-44</sup> (see Appendix VI - Comprehensive Version)
- Brachytherapy<sup>45-47</sup> (seed implant- see Appendix VI- Comprehensive Version)

- not available in Nova Scotia
- Expectant Management<sup>22,48-51</sup>
- Observation<sup>13,52-54</sup>

#### 5.2.2 Intermediate Risk:

T2b-T2c  
**or**  
PSA = 10-19 ng/mL  
**or**  
Gleason Grade = 7:

#### Treatment Options:

Patients may choose one of these options in discussion with their doctor<sup>13,33</sup>

- Radical prostatectomy<sup>14,16,25,35-37</sup> with or without pelvic lymph node dissection (PLND)
- Neoadjuvant Androgen deprivation therapy (ADT- also known as hormonal therapy) (see Appendix VII- Comprehensive Version) and radical external beam radiotherapy<sup>55</sup>
  - ADT given for 2-8 months prior to radiotherapy<sup>56</sup>
  - ADT concurrent with radiotherapy may be given<sup>55</sup>
- Dose-escalated conformal external beam radiotherapy (3D)<sup>25,57</sup>
- ADT may be used as primary treatment if contraindication to radiotherapy and radical prostatectomy.
- Expectant Management<sup>53</sup>
- Observation<sup>13,34,53,58</sup>

#### 5.2.3 High Risk:

T3-T4  
**or**  
Gleason Grade  $\geq 8$   
**or**  
PSA > 20ng/mL

#### Treatment Options:

Patients may choose one of these options in discussion with their doctor<sup>59</sup>

- Neoadjuvant ADT<sup>25,55,56,60-62</sup> and external beam radiotherapy (including elective treatment of pelvic

lymph nodes<sup>63,64</sup>) (see Section 5.2.2) with or without 2-3 years of adjuvant ADT<sup>55,56,65-69</sup>

- Radical prostatectomy<sup>70-73</sup> – for highly selected patients with low volume disease; Not recommended for T3b-T4 patients
  - Post operative radiotherapy and/or ADT may be required
- ADT may be used as primary treatment in very high risk patients with low chance of cure<sup>74-76</sup>
- Observation<sup>77</sup>

### 5.3 Post-Prostatectomy Management

#### Post-operative PSA Undetectable or PSA < 0.2mg/mL

##### pT2, pT0 NX,N0 M0 negative margin

- Observation, standard follow-up management<sup>25</sup>

##### pT2 (positive margin), pT3a NX,N0 M0

Options:

- Radiation Therapy<sup>4,10,78-82</sup> (+/- ADT)
- Observation, standard follow-up management

##### pT3b NX,N0 M0

Options:

- Radiation Therapy<sup>4,10,78-82</sup> (+/- ADT)
- ADT alone
- Observation, standard follow-up management<sup>25</sup>

##### pT4 NX,N0 M0

Options:

- Radiation Therapy (+/-ADT)
- ADT alone

##### pTX N+ M0

Options:

- ADT<sup>25,83</sup>
- Observation, standard follow-up management

#### Post-operative PSA Detectable

PSA ≥ 0.2 ng/mL – See Salvage Therapy Section 5.4

## 5.4 Salvage therapy

### 5.4.1 Salvage Radiotherapy Post-Radical Prostatectomy<sup>25,79,81,84,85</sup>

Should be considered in the setting of rising PSA (on at least two subsequent measurements) after radical prostatectomy (minimum PSA > 0.2 ng/dL) or first post-operative PSA > 0.2 ng/dL in patients who are more likely to have disease isolated to the prostatic bed.

Biochemical relapse-free survival (but not overall survival) is superior if radiotherapy initiated when PSA < 1 ng/dL, and PSA doubling time > 10 months, and PSA recurrence post-prostatectomy > 18 months

### 5.4.2 Salvage Therapy Post-Radiotherapy<sup>25</sup>

In a highly selected subset of patients (e.g. low risk disease at diagnosis and long PSA doubling time and long disease-free interval) with three consecutive rises in PSA 3-4 months apart<sup>86</sup> **and** PSA ≥ 1.5 ng/mL, options may include:

- Prostatectomy
- Brachytherapy/seed implant
  - not available in Nova Scotia
- Cryotherapy
  - not available in Nova Scotia

## 5.5 Metastatic Cancer of the Prostate

Patients with metastatic or clinically detectable lymph node disease are considered to be incurable and are generally offered immediate ADT<sup>76,87</sup>. This could include:

- LHRH agonist<sup>74,88-93</sup>
- LHRH agonist plus antiandrogen<sup>92-94</sup>
- Orchiectomy<sup>74,95,96</sup>

Other patients who have extremely high-risk disease (without proven distant disease) who are unlikely to be cured and/or those who have significant co-morbid disease may be considered for immediate or delayed ADT alone<sup>55</sup>.

## 5.6 Hormone Refractory Prostate Cancer

Hormone refractory prostate cancer is defined by rising PSA, worsening radiographic disease, or worsening symptoms while on ADT. Castrate testosterone levels should be confirmed (< 1.75 nmol/L) and effective ADT implemented if not the case.

Secondary hormonal manipulations may be indicated. These may include:

- Addition of antiandrogen agent to orchiectomy or LHRH agonist<sup>92-94</sup> (See Appendix VII- Comprehensive Version)
- Discontinuation of antiandrogen if patient has been receiving one<sup>97-100</sup>
- Other less commonly-used manipulations<sup>101</sup> (See Appendix VII- Comprehensive Version)

Symptom control should be optimized, especially analgesic therapy and supportive measures. The palliative care team should be consulted. Other interventions aimed at improving symptom control may include:

- Urological intervention (e.g. TURP)
- Radiotherapy (localized or hemi-body)<sup>102</sup>
- Low dose steroids<sup>103</sup> (i.e., prednisone 5-10 mg/day or dexamethasone 1-2 mg/day)
- Systemic radionuclides<sup>104-106</sup>

(See Appendix X- Comprehensive Version)

- Palliative chemotherapy (See Appendix VIII- Comprehensive Version)

- Docetaxel plus prednisone<sup>106-107</sup>

(See Appendix IX- Comprehensive Version)

- Mitoxantrone plus prednisone<sup>108</sup>
- Bisphosphonate therapy
  - Data is emerging to indicate zoledronic acid decreases skeletal events (e.g. pathologic fractures, need for radiotherapy, need for surgery, spinal cord compression) and decreases pain in hormone refractory prostate cancer<sup>109</sup>.

## References:

1. Matzkin H, Eber P, Todd B, et al.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. *Cancer*, 1992; 70 (9): 2302-9.
2. Pisansky TM, Cha SS, Earle JD, et al.: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. *J Clin Oncol*, 1993; 11 (11): 2158-66.
3. Carlton JC, Zagars GK, Oswald MJ: The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. *Int J Radiat Oncol Biol Phys*, 1990; 19 (6): 1383-8.
4. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med*, 1987; 317 (15): 909-16.
5. Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. *J Urol*, 1989; 141 (5): 1070-5.
6. Stamey TA, Kabalin JN, McNeal JE, et al.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. *J Urol*, 1989; 141 (5): 1076-83.
7. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. *J Urol*, 1989; 141 (5): 1084-7.
8. Andriole GL: Serum prostate-specific antigen: the most useful tumor marker. *J Clin Oncol*, 1992; 10 (8): 1205-7.
9. Gittes RF: Carcinoma of the prostate. *N Engl J Med*, 1991; 324 (4): 236-45.
10. Paulson DF, Moul JW, Walther PJ: Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. *J Urol*, 1990; 144 (5): 1180-4.
11. Matzkin H, Eber P, Todd B, et al.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. *Cancer*, 1992; 70 (9): 2302-9.
12. Pisansky TM, Cha SS, Earle JD, et al.: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. *J Clin Oncol*, 1993; 11 (11): 2158-66.
13. Chodak GW, Thisted RA, Gerber GS, et al.: Results of conservative management of clinically localized prostate cancer. *N Engl J Med*, 1994; 330 (4): 242-8.
14. Catalona WJ, Bigg SW: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. *J Urol*, 1990; 143 (3): 538-43; discussion 544.
15. Corral DA, Bahnson RR: Survival of men with clinically localized prostate cancer detected in the eighth decade of life. *J Urol*, 1994; 151 (5): 1326-9.

16. Zincke H, Bergstralh EJ, Blute ML, et al.: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. *J Clin Oncol*, 1994; 12 (11): 2254-63.
17. Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development. *Can J Urol*, 2001; 8 (4): 1314-22
18. Pisansky TM, Kahn MJ, Rasp GM, et al.: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. *Cancer*, 1997; 79 (2): 337-44.
19. Asbell SO, Martz KL, Shin KH, et al.: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. *Int J Radiat Oncol Biol Phys*, 1998; 40 (4): 769-82.
20. Forman JD, Order SE, Zinreich ES, et al.: Carcinoma of the prostate in the elderly: the therapeutic ratio of definitive radiotherapy. *J Urol*, 1986; 136 (6): 1238-41.
21. Zietman AL, Coen JJ, Shipley WU, et al.: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. *J Urol*, 1994; 151 (3): 640-5.
22. Adolfsson J, Steineck G, Whitmore WF Jr: Recent results of management of palpable clinically localized prostate cancer. *Cancer*, 1993; 72 (2): 310-22.
23. Barry MJ, Albertsen PC, Bagshaw MA, et al.: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. *Cancer* 91 (12): 2302-14, 2001.
24. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. *Lancet* 349 (9056): 906-10, 1997.
25. National Comprehensive Cancer Network Practice Guidelines in Oncology, Prostate Cancer v.1.2005. NCCN, 2005
26. Whitmore WF Jr: Expectant management of clinically localized prostatic cancer. *Semin Oncol*, 1994; 21 (5): 560-8.
27. Partin AW, Kattan MW, Subong EN, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA*, 1997; 277 (18): 1445-51.
28. Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. *Urology*, 2001; 58 (6): 843-8.
29. Kattan MW, Eastham JA, Stapleton AM, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. *J Natl Cancer Inst*, 1998; 90 (10): 766-71.
30. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. *J Clin Oncol*, 1999; 17 (5): 1499-507.
31. Wasson JH, Cushman CC, Bruskewitz RC, et al.: A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. *Arch Fam Med*, 1993; 2 (5): 487-93.
32. Chodak GW, Thisted RA, Gerber GS, et al.: Results of conservative management of clinically localized prostate cancer. *N Engl J Med*, 1994; 330 (4): 242-8.
33. Epstein JI, Paull G, Eggleston JC, et al.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. *J Urol*, 1986; 136 (4): 837-9.
34. Holmberg L, Bill-Axelsson A, Helgesen F, et al.: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. *N Engl J Med*, 2002; 347 (11): 781-9.
35. Catalona WJ, Basler JW: Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. *J Urol*, 1993; 150 (3): 905-7.
36. Eastham JA, Scardino PT: Radical prostatectomy. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: *Campbell's Urology*. 8th ed. Philadelphia: Saunders, 2002, pp 3080-3083.
37. Paulson DF, Lin GH, Hinshaw W, et al.: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. *J Urol*, 1982; 128 (3): 502-4.
38. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; 280:969-974.
39. Bagshaw MA: External radiation therapy of carcinoma of the prostate. *Cancer*, 1980; 45 (7 Suppl): 1912-21.
40. Forman JD, Zinreich E, Lee DJ, et al.: Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate. *Int J Radiat Oncol Biol Phys*, 1985; 11 (12): 2073-80.
41. Ploysongsang S, Aron BS, Shehata WM, et al.: Comparison of whole pelvis versus small-field radiation therapy for carcinoma of prostate. *Urology*, 1986; 27 (1): 10-6.
42. Pilepich MV, Bagshaw MA, Asbell SO, et al.: Definitive radiotherapy in resectable (stage A2 and B) carcinoma of the prostate--results of a nationwide overview. *Int J Radiat Oncol Biol Phys*, 1987; 13 (5): 659-63.
43. Amdur RJ, Parsons JT, Fitzgerald LT, et al.: The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. *Int J Radiat Oncol Biol Phys*, 1990; 19 (6): 1377-82.
44. Perez CA, Garcia D, Simpson JR, et al.: Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. *Radiother Oncol*, 1989; 16 (1): 1-21.
45. Ragde H, Blasko JC, Grimm PD, et al.: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. *Cancer*, 1997 80 (3): 442-53.

46. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. *J Clin Oncol*, 1996; 14 (2): 449-53.
47. D'Amico AV, Coleman CN: Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. *J Clin Oncol*, 1996; 14 (1): 304-15.
48. Consensus conference. The management of clinically localized prostate cancer. *JAMA*, 1987; 258 (19): 2727-30.
49. Carter HB, Walsh PC, Landis P et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. *J Urol* 2002; 167:1231-1234.
50. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. *J Urol* 2002; 167:1664-1669.
51. Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. *Urology* 2002; 59:652-656.
52. Epstein JI, Paull G, Eggleston JC, et al.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. *J Urol*, 1986; 136 (4): 837-9.
53. Graverson PH, Nielsen KT, Gasser TC, et al.: Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. *Urology*, 1990; 36 (6): 493-8.
54. Cantrell BB, DeKlerk DP, Eggleston JC, et al.: Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. *J Urol*, 1981; 125 (4): 516-20.
55. Seidenfeld J, Samson DJ, Aronson N, et al.: Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. *Evid Rep Technol Assess (Summ)*, 1999; (4): i-x, 1-246, 11-36, passim.
56. Pilepich MV, Winter K, John MJ, et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. *Int J Radiat Oncol Biol Phys*, 2001; 50 (5): 1243-52.
57. Hanks GE, Hanlon AL, Schultheiss TE, et al.: Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. *Int J Radiat Oncol Biol Phys*, 1998; 41 (3): 501-10.
58. Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. *N Engl J Med*, 2002; 347 (11): 790-6.
59. del Regato JA, Trailins AH, Pittman DD: Twenty years follow-up of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy: report of a national cooperative study. *Int J Radiat Oncol Biol Phys*, 1993; 26 (2): 197-201.
60. Pilepich MV, Caplan R, Byhardt RW, et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. *J Clin Oncol*, 1997; 15 (3): 1013-21.
61. Bolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. *N Engl J Med*, 1997; 337 (5): 295-300.
62. Seymore CH, el-Mahdi AM, Schellhammer PF: The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. *Int J Radiat Oncol Biol Phys*, 1986; 12 (9): 1597-600.
63. Roach M 3rd, DeSilvio M, Lawton C, et al.: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol*, 2003; 21 (10): 1904-11.
64. Pollack A: A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer. *J Clin Oncol*, 2003; 21 (10): 1899-901.
65. Lawton CA, Winter K, Murray K, et al.: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. *Int J Radiat Oncol Biol Phys*, 2001; 49 (4): 937-46.
66. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. *Lancet*, 2002; 360 (9327): 103-6.
67. Zagars GK, Johnson DE, von Eschenbach AC, et al.: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. *Int J Radiat Oncol Biol Phys*, 1988; 14 (6): 1085-91.
68. Granfors T, Modig H, Damber JE, et al.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. *J Urol*, 1998; 159 (6): 2030-4.
69. Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group. *Urology* 1995; 45 (4):616-623.
70. Walsh PC, Jewett HJ: Radical surgery for prostatic cancer. *Cancer*, 1980; 45 (7 Suppl): 1906-11.
71. Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. *Urology*, 1989; 33 (5 Suppl): 27-36.

72. Lau WK, Bergstralh EJ, Blute ML et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. *J Urol* 2002; 167:117-122.
73. Ohori M, Goad J, Wheeler J et al. Can radical prostatectomy alter the progressing of poorly differentiated prostate cancer? *J.Urol.* 1994; 152:1843-1849.
74. Seidenfeld J, Samson DJ, Hasselblad V, et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. *Ann Intern Med*, 2000.; 132 (7): 566-77 .
75. Kirk D: Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? (Abstract) *BJU Int*, 2000; 86 (Suppl 3): 218-58.
76. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. *Br J Urol*, 1997; 79 (2): 235-46.
77. Adolfsson J: Deferred treatment of low grade stage T3 prostate cancer without distant metastases. *J Urol*, 1993; 149 (2): 326-8; discussion 328-9.
78. Lange PH, Reddy PK, Medini E, et al.: Radiation therapy as adjuvant treatment after radical prostatectomy. *NCI Monogr*, 1988; (7): 141-9.
79. Ray GR, Bagshaw MA, Freiha F: External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. *J Urol*, 1984; 132 (5): 926-30.
80. Carter GE, Lieskovsky G, Skinner DG, et al.: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. *J Urol*, 1989; 142 (5): 1266-70; discussion 1270-1.
81. Freeman JA, Lieskovsky G, Cook DW, et al.: Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: intermediate findings. *J Urol*, 1993; 149 (5): 1029-34.
82. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. *J Urol*, 1989; 142 (4): 1011-7.
83. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J Med*, 1999; 341 (24): 1781-8.
84. Carter GE, Lieskovsky G, Skinner DG, et al.: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. *J Urol* 142 (5): 1266-70; discussion 1270-1, 1989.
85. Moul JW, Paulson DF: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. *Cancer*, 1991; 68 (6): 1265-71.
86. Cox JD, Gallagher MJ, Hammond EH et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. *J Clin Oncol* 1999; 17:1155.
87. Scott WW, Menon M, Walsh PC: Hormonal therapy of prostatic cancer. *Cancer*, 1980; 45 (7 Suppl): 1929-36.
88. Peeling WB: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. *Urology*, 1989; 33 (5 Suppl): 45-52.
89. Vogelzang NJ, Chodak GW, Soloway MS, et al.: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. *Urology*, 1995; 46 (2): 220-6.
90. Kaisary AV, Tyrrell CJ, Peeling WB, et al.: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. *Br J Urol*, 1991; 67 (5): 502-8.
91. Sharifi R, Soloway M: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. *J Urol*, 1990; 143 (1): 68-71.
92. Parmar H, Edwards L, Phillips RH, et al.: Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. *Br J Urol*, 1987; 59 (3): 248-54.
93. Waymont B, Lynch TH, Dunn JA, et al.: Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. *Br J Urol*, 1992; 69 (6): 614-20.
94. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. *Lancet*, 2000; 355 (9214): 1491-8.
95. Cassileth BR, Soloway MS, Vogelzang NJ, et al.: Patients' choice of treatment in stage D prostate cancer. *Urology*, 1989; 33 (5 Suppl): 57-62.
96. Byar DP: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. *Cancer*, 1973; 32 (5): 1126-30.
97. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. *J Clin Oncol*, 1993; 11 (8): 1566-72.
98. Sartor O, Cooper M, Weinberger M, et al.: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. *J Natl Cancer Inst*, 1994; 86 (3): 222-7.
99. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. *Cancer*, 1995; 76 (8): 1428-34.

- 100.Sridhara R, Eisenberger MA, Sinibaldi VJ, et al.: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. *J Clin Oncol*, 1995; 13 (12): 2944-53.
- 101.Small EJ, Halabi S, Dawson NA, et al.: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). *J Clin Oncol*, 2004; 22 (6): 1025-33.
- 102.Porter AT, McEwan AJ, Powe JE, et al.: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys*, 1993; 25 (5): 805-13.
- 103.Debruyne FJ, Murray R, Fradet Y, et al.: Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. *Urology*, 1998; 52 (1): 72-81.
- 104.Bolger JJ, Dearnaley DP, Kirk D, et al.: Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. *Semin Oncol*, 1993; 20 (3 Suppl 2): 32-3.
- 105.Oosterhof GO, Roberts JT, de Reijke TM, et al.: Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. *Eur Urol*, 2003; 44 (5): 519-26.
- 106.Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*, 2004; 351 (15): 1502-12.
- 107.Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med*, 2004; 351 (15): 1513-20.
- 108.Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol*, 1996; 14; 1756-1764.
- 109.Saad F, Gleason DM, Murray R, et al. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma. *J Natl Cancer Inst* 2002; 94: 1458-1468.

## Part 6. Follow-up

### 6.1 Follow-up after Curative Therapy

The goal of follow up after curative therapy is to detect recurrence and to monitor for side effects from the treatment. In addition, followup visits should include reassessment and management of any supportive care issues, including psychosocial, sexual and/or incontinence problems. The follow up schedule after curative radiotherapy or radical prostatectomy will depend on a number of factors<sup>1</sup>, including the initial clinical or pathological stage of the disease, acute or chronic toxicities, the post therapy PSA levels, or rising PSA levels. The following schedules are recommended after each of these curative treatments. The physician should review the followup schedule with each patient before completion of initial treatment, so that the patient has an understanding of what to expect.

#### 6.1.1 Follow-up after Curative Radiotherapy

Year	Frequency	Provider	Tests
1-5	every 6-24 months	RO	Clinical assessment, DRE
1-5	every 3-4 months	RO	PSA *
>5	every 1-3 years	RO	Clinical assessment, DRE
>5	every 3-6 months	RO	PSA

\* Serum testosterone may be monitored in patients receiving ADT

RO: radiation oncologist, for follow-up of treatment effectiveness and long-term toxicity  
DRE: digital rectal examination  
PSA: prostate specific antigen

#### 6.1.2 Followup after Curative Radical Prostatectomy

Year	Frequency	Provider	Tests
1-3	every 3-12 months	U	PSA, Clinical assessment
3- Ongoing	every 6-12 months	U	PSA, Clinical assessment

U: urologist

PSA: prostate specific antigen

### 6.2 Follow-up for patients with Metastatic Disease

The interval, investigations, and providers will be determined by the patient's clinical condition and symptoms.

#### References:

1. National Comprehensive Cancer Network  
Practice Guidelines in Oncology, Prostate Cancer  
v.1.2005. NCCN, 2005

## Part 7. Supportive Care Issues

### 7.1 Psychosocial Needs

Prostate cancer patients, like all cancer patients, may have a number of supportive care needs, often including the need for psychosocial support<sup>1,2</sup>. The psychosocial needs will differ from newly diagnosed men, to those living with the cancer, and to those who fail treatment.

Psychosocial support may be needed for help to cope with the cancer experience. For some patients, mental health support may be needed. There is about 25% chance of clinically significant depression, anxiety and adjustment difficulties<sup>3-6</sup>. In addition, one must also pay attention to the impact of the cancer on the patient's partner. Prostate cancer and its treatment may cause or exacerbate erectile dysfunction<sup>7,8</sup>, urinary incontinence, a change in mood and sleep patterns. It is the responsibility of the attending health caregivers to provide basic support through the continuum of disease. This should include basic screening for signs of depression<sup>12,13</sup> in the patient. Where available, cancer patient navigators are a valuable resource for patients. There may be peer support groups in local communities to help patients.

Screening for distress (see Section 8.12) should be included in patient visits at diagnosis and other key transition points (e.g. six months after treatment completion, disease recurrence, progression to advanced disease). For high risk patients, distress screening should be included at each visit. Risk factors to consider in selecting the frequency of distress screening include<sup>14</sup>:

- age < 60
- mental health history
- social isolation
- receiving ADT (hormone therapy)
- greater burden of illness

- advanced stage of cancer
- unresolved urinary incontinence
- high sexual dissatisfaction
- multiple life stressors

If possible, partners should be involved in the process of screening for distress.

If there are specific needs beyond the abilities of the front-line caregivers, a referral to the Psychosocial Oncology Team at either of the Cancer Centres, or an appropriate local resource (eg. mental health specialists), may be considered. Specialized psychosocial support may be offered by psychosocial counsellors, psychologists, psychiatrists, social workers, clinical nurse specialists, or other trained professionals.

### 7.2 Symptom Management

The treatment of prostate cancer is complex and may include surgery, external beam radiotherapy, brachytherapy, ADT, or chemotherapy. These treatments have specific and overlapping side effects, which may affect quality of life. Common side effects include erectile dysfunction, urinary incontinence, loss of libido, hot flashes, and mood swings.

#### 7.2.1 Erectile Dysfunction and Sexual Health

Following prostate cancer treatment, there is a high incidence of erectile dysfunction (ED)<sup>15-19</sup>, up to 85% depending on the treatment. Prior to treatment, 30-40% of men report pre-existing ED as a result of other factors<sup>7,8,20</sup>. Therefore, it is important to assess sexual issues prior to treatment, to determine baseline and to identify the degree of concern for the patient and his partner<sup>8-11,21,22</sup>. This assessment can identify many issues beyond baseline ED. It is recommended that the man's partner should be allowed to participate in the pre-treatment assessment<sup>23</sup>. (Query their

current level of sexual activity, how satisfied they are with this and how concerned they are about possible changes.) If necessary, consider initiation of sexual counselling to address aspects of the couple's relationship<sup>24,25</sup>.

Following radical prostatectomy or radical radiotherapy, at 6-12 weeks post-treatment, a visit should be planned to discuss possible resumption of sexual activity (including issues such as the return of erections, morning fullness)<sup>26-30</sup>. At this time, consideration may be given to initiate oral therapy with a phosphodiesterase enzyme inhibitor<sup>31-38</sup> (e.g. sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levitra®)) to stimulate erectile tissue. It is important to note with the patients that the purpose of these oral agents is to preserve tissue and enhance penile health, not necessarily for sexual relations.

A follow-up visit should be planned for 3-12 months after treatment to discuss the couple's sexual function and satisfaction. If the oral agent is not working, consider prostaglandin injections<sup>39-41</sup> (e.g. alprostadil (Caverject®)) and a referral to erectile dysfunction (ED) clinic (Note: only available in Halifax). Another option could be referral for couples counselling or sex therapy, where available. This should be re-assessed at 12 months, or as necessary.

### **7.2.2 Urinary Incontinence**

Urinary incontinence is another common consequence of prostate cancer treatment<sup>24,25</sup>. This can be very distressing to patients, especially if not addressed early in the treatment. This potential adverse effect should also be discussed before treatment, along with an assessment of pre-treatment bladder function. Patients should be instructed on Kegel exercises and advised on the use of incontinence products.

About 2-3 weeks after surgery, the catheter is usually removed. Upon removal of the catheter, patients should be able to demonstrate Kegel exercises. There should also be a discussion with the patient about incontinence. Patients often need reassurance that this is expected, and they may need information on different incontinence products.

At three months after treatment, a follow-up visit should be planned to discuss how the patient is doing with incontinence. If possible, a referral for urodynamic assessment (where available) may be considered to assess options for bio-feedback training to help the patient regain control.

If the patient is still having trouble with incontinence problems at 12 months post-treatment, consider referral for an incontinence device (a pump that is inserted during day surgery).

### **7.2.3 Loss of Libido, Hot Flashes, Mood Swings**

These symptoms are caused by testosterone reduction and occur during hormonal treatment, and possibly for months to years afterwards. Supportive care and or medications (see Appendix VII) may be considered.

### **7.2.4 Proctitis**

Chronic irritation of the lower rectum occurs in about 10% percentage of prostate cancer patients treated with external radiation. The symptom of mild rectal bleeding usually develops within 6-12 months after radiation, due to vessel telangiectasia. It may last for years, usually improving with time. Proctitis may also cause discomfort during defecation or rectal urgency.

Any patient with persistent rectal bleeding needs full assessment including

colonoscopy by a gastroenterologist or surgeon. Once confirmed, radiation-induced proctitis can be treated symptomatically by modifying diet (to ensure avoidance of constipation) and with medications or procedures, listed below.

For patients with clinically significant symptoms of proctitis (rectal urgency, tenesmus, pain with bowel movements) treatment with either Anusol®- HC (*Hydrocortisone Acetate – Zinc Sulfate*) suppositories 1 PR q8h prn or Proctosone® or Proctosedyl® (*Hydrocortisone Acetate – Framycetin Sulfate – Cinchocaine HCL – Esculin*) suppositories 1 PR q8h prn, is recommended. If these do not provide adequate relief, Proctofoam™- HC (*Hydrocortisone Acetate – Pramoxine HCL*), Anugesic® - HC (*Pramoxine HCL – Hydrocortisone Acetate – Zinc Sulfate*), Xylocaine® (*Lidocaine HCL*) jelly 2%, all given PR q8h prn, or oral analgesics can be prescribed, in severe cases.

For bleeding occurring more than one year after radiation treatment, mesalamine (Salofalk®, Rowasa®) suppositories 1000mg PR for two weeks, repeated on a monthly basis, can be helpful. Occasionally, local therapy such as laser treatment is required for refractory bleeding requiring transfusion. Hyperbaric oxygen can also be helpful for recurrent bleeding. If life-threatening bleeding occurs, instillation of Formalin has also been shown to be effective to stop bleeding. In cases of complete, persistent incontinence, severe refractory rectal pain or fistula, defunctioning colostomy should be considered.

### 7.3 Other Resources

Some prostate cancer patients may benefit from involvement of the local palliative care service, for advanced symptom management expertise and end of life care when appropriate.

Referral to palliative care is available across the province, as illustrated in Figure 8.13.

Guidelines for the management of symptoms are under development by the CCNS Supportive Care Cancer Site Team. As these guidelines are completed, they are posted on the *Cancer Care Nova Scotia* website ([www.cancercare.ns.ca](http://www.cancercare.ns.ca)). Current CCNS symptom management guidelines are:

- Management of Nausea & Vomiting (2004)
- Management of Cancer-Related Pain (2006)
- Management of Oral Complications from Cancer Therapy (2006)


#### References:

1. Roth AJ, Holland JC: Psychiatric complications in cancer patients. In: Brain MC, Carbone PP, eds.: *Current Therapy in Hematology-Oncology*. 5th ed. St. Louis, Mo: Mosby-Year Book, Inc., 1995, pp 609-18.
2. Breitbart W, Holland JC: Psychiatric complications of cancer. *Current Therapy in Hematology-Oncology*, 1988; 3: 268-74.
3. Block SD: Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. *Ann Intern Med*, 2000; 132 (3): 209-18.
4. Petersen RW, Quinlivan JA: Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. *BJOG*, 2002; 109 (4): 386-94.
5. Lynch ME: The assessment and prevalence of affective disorders in advanced cancer. *J Palliat Care*, 1995 Spring; 11 (1): 10-8.
6. Block, Susan. "Assessing and Managing Depression in the Terminally Ill Patient." *Annals of Internal Medicine*, 2000; 132.3 :209-218.
7. Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. *N Engl J Med*, 2002; 347 (11): 790-6.
8. Bokhour BG, Clark JA, Inui TS, et al.: Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". *J Gen Intern Med*, 2001; 16 (10): 649-55.
9. Auchincloss SS: Sexual dysfunction in cancer patients: issues in evaluation and treatment. In: Holland JC, Rowland JH, eds.: *Handbook of Psychooncology: Psychological Care of the Patient With Cancer*. New York, NY: Oxford University Press, 1989, pp 383-413.

10. Schover LR: *Sexuality and Fertility After Cancer*. New York, NY: John Wiley and Sons, 1997.
11. Lamb MA: *Sexuality and Sexual Functioning*. In: McCorkle R, Grant M, Frank-Stromborg M, et al., eds.: *Cancer Nursing: A Comprehensive Textbook*. 2nd ed. Philadelphia, Pa: WB Saunders Co, 1996; pp 1105-1127.
12. Passik SD, Dugan W, McDonald MV, et al.: Oncologists' recognition of depression in their patients with cancer. *J Clin Oncol*, 1998; 16 (4): 1594-600.
13. Roth AJ, Kornblith AB, Batel-Copel L, et al.: Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. *Cancer*, 1998; 82 (10): 1904-8.
14. Roth AJ, Holland JC: Treatment of depression in cancer patients. *Primary Care and Cancer*, 1994; 14: 23-9.
15. Walsh PC, Epstein JI, Lowe FC: Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. *J Urol* 138 (4): 823-7, 1987.
16. Talcott JA, Rieker P, Clark JA, et al.: Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. *J Clin Oncol*, 1998; 16 (1): 275-83.
17. Smith DS, Carvalhal GF, Schneider K, et al.: Quality-of-life outcomes for men with prostate carcinoma detected by screening. *Cancer*, 2000.; 88 (6): 1454-63
18. Stanford JL, Feng Z, Hamilton AS, et al.: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. *JAMA*, 2000; 283 (3): 354-60.
19. Robinson JW, Moritz S, Fung T: Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. *Int J Radiat Oncol Biol Phys*, 2002; 54 (4): 1063-8.
20. Helgason AR, Adolfsson J, Dickman P, et al.: Factors associated with waning sexual function among elderly men and prostate cancer patients. *J Urol* , 1997;158 (1): 155-9.
21. Litwin MS, Hays RD, Fink A, et al.: Quality-of-life outcomes in men treated for localized prostate cancer. *JAMA*, 1995; 273 (2): 129-35.
22. Lamb MA, Woods NF: Sexuality and the cancer patient. *Cancer Nurs*, 1981; 4 (2): 137-44.
23. McNeff EA: Issues for the partner of the person with a disability. In: Sipski ML, Alexander CJ, eds.: *Sexual Function in People With Disability and Chronic Illness*. Gaithersburg, Md: Aspen Publishers, Inc, 1997, pp 595-616.
24. Bates TS, Wright MP, Gillatt DA: Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. *Eur Urol*, 1998; 33 (2): 165-9.
25. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al.: Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. *Cancer*, 1997; 79 (10): 1977-86.
26. Kaplan HS: *The Evaluation of Sexual Disorders: Psychological and Medical Aspects*. New York, NY: Brunner/Mazel Inc, 1983.
27. Lue TF: *Contemporary Diagnosis and Management of Male Erectile Dysfunction*. Newton, Pa: Handbooks in Health Care, 1999.
28. Costabile RA: Cancer and male sexual dysfunction. *Oncology (Huntingt)*, 2000; 14 (2): 195-200, 203; discussion 203-5.
29. Rivas DA, Chancellor MB: Management of erectile dysfunction. In: Sipski ML, Alexander CJ, eds.: *Sexual Function in People With Disability and Chronic Illness*. Gaithersburg, Md: Aspen Publishers, Inc, 1997, pp 429-464.
30. Ducharme SH, Gill KM: Management of other male sexual dysfunctions. In: Sipski ML, Alexander CJ, eds.: *Sexual Function in People With Disability and Chronic Illness*. Gaithersburg, Md: Aspen Publishers, Inc, 1997, pp 465-486.
31. National Comprehensive Cancer Network Practice Guidelines in Oncology, Prostate Cancer v.1.2005. NCCN, 2005
32. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *N Engl J Med* 338 (20): 1397-404, 1998.
33. Zippe CD, Jhaveri FM, Klein EA, et al.: Role of Viagra after radical prostatectomy. *Urology*, 2000; 55 (2): 241-5.
34. Raina R, Lakin MM, Agarwal A, et al.: Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. *Urology*, 2003; 62 (1): 110-5.
35. Raina R, Agarwal A, Goyal KK, et al.: Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. *Urology*, 2003; 62 (6): 1103-8.
36. Potters L, Torre T, Fearn PA, et al.: Potency after permanent prostate brachytherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*, 2001; 50 (5): 1235-42.
37. Merrick GS, Butler WM, Galbreath RW, et al.: Erectile function after permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys*, 2002; 52 (4): 893-902.
38. Lindsey I, George B, Kettlewell M, et al.: Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. *Dis Colon Rectum*, 2002; 45 (6): 727-32.
39. Dewire DM, Todd E, Meyers P: Patient satisfaction with current impotence therapy. *Wis Med J*, 1995; 94 (10): 542-4.
40. Jarow JP, Nana-Sinkam P, Sabbagh M, et al.: Outcome analysis of goal directed therapy for impotence. *J Urol*, 1996; 155 (5): 1609-12.
41. Hanash KA: Comparative results of goal oriented therapy for erectile dysfunction. *J Urol*, 1997; 157 (6): 2135-8.

## Part 8. Practice Pathways

### 8.1 Diagnosis and Referral of Prostate Cancer- Overview



#### Referral Information:

A letter of referral is the minimal requirement for a referral. A referral need not be delayed due to delays in scheduling tests or delayed reporting of tests

#### Local Urologist

- Refer as per usual practice within local community or health care district

#### QEII Health Sciences Centre:

- Faxed referrals to the QEII Cancer Care Program (CCP) Referrals Office at 902-473-6079 (tel. 902-473-5140 or 902-473-6098). It is preferred that referrals be accompanied by the CCP Referral form available upon request at the above phone numbers or available for downloading at [www.cdha.nshhealth.ca/physicianupdate](http://www.cdha.nshhealth.ca/physicianupdate)

#### Cape Breton Cancer Centre:

- Direct referrals to the Referrals/Booking office at 902-567-7774 (fax 902-567-7911)

#### Urgent Referrals:


- For urgent or emergent referrals, in Halifax- page the appropriate specialist on call through the Locating service (902-473-2220); in Cape Breton- page the appropriate specialist on call through the Locating service (902-567-8000)

#### Referral Information:

- Letter of Referral\*
- Laboratory Results\*- CBC, PSA (including old results)
- Biopsy Pathology Reports
- Operative Reports (prostatectomy, orchiectomy, other)
- Diagnostic Imaging Reports (TURP, bone scans, chest X-ray, CT scans, other)

\* Specific information which is necessary for proper triage of referrals

## 8.2 Initial Treatment Options for Prostate Cancer



## 8.3 Observation

- Observation consists of medical follow up where it is unlikely that the patient will be treated with radiation therapy or surgery for cure due to a limited life expectancy or severe medical co-morbidities. Treatment at symptomatic progression will likely consist of ADT with additional interventions given with the intent of improving impairments in prostate cancer-specific health-related quality of life.

## 8.4 Expectant Management

- Expectant management involves actively monitoring the course of disease with the expectation to intervene if the cancer progresses or if symptoms become imminent
- Patients with clinically localized cancers that are candidates for definitive treatment and choose expectant management should have regular follow up
  - DRE and PSA every six months
  - Needle biopsy of the prostate may be repeated within 6 mo of diagnosis if initial biopsy was < 10 cores or assessment discordant (eg, palpable tumour contralateral to side of positive biopsy)
  - Needle biopsy should be performed within 18 months if > 10 cores obtained initially, then periodically
- A repeat biopsy may be indicated for any sign of disease progression by exam or markers

## 8.5 ADT (Androgen Deprivation Therapy - Hormonal Regimens)

The choice of initial orchiectomy or androgen deprivation (hormonal) agent(s) for any individual patient will depend on many factors.

- Combined Androgen Blockade (CAB- LHRH agonist plus non-steroidal antiandrogen agent) is not routinely indicated
- Monotherapy with nonsteroidal antiandrogens is not routinely indicated
- After initial failure of ADT, secondary hormonal manipulation should be tried (eg. addition of a non-steroidal antiandrogen or discontinuation of non-steroidal antiandrogen if already on)
- Other hormonal manipulations, such as ketoconazole or estrogens may be tried. Some phase II trials show a decline in PSA. There are no randomized data to support any survival advantage

### OPTIONS:

#### 1. Orchiectomy

The testicles are surgically removed. The procedure is done as an outpatient, usually done under local anesthetic. Surgical castration (orchiectomy) is permanent.

#### 2. LHRH Agonists

Goserilin (Zoladex®) 3.6 mg SC Depot q28d OR 10.8 mg SC Depot q84d  
Leuprolide (Lupron®-IM, Eligard®-SC) 7.5 mg q28d OR 22.5 mg q84d (3mo) IM/SC Depot  
OR 30 mg q112d (4 mo)/ 45 mg q168d (6mo) SC Depot  
Buserilin (Suprefact®) 6.3 mg SC Depot q56d OR 9.45 mg IM Depot q120d

Note: Due to an initial rise in testosterone levels, patients should be given a non-steroidal antiandrogen (see below) for 2-4 weeks at the same time as their first LHRH agonist dose


#### 3. Non-steroidal Antiandrogen Agents

Flutamide (Euflex®) 250 mg PO TID  
Bicalutamide (Casodex®) 50 mg PO daily, up to 150 mg PO daily to TID  
Nilutamide (Anandron®) 50 mg PO BID or TID


#### 4. Other Hormonal Treatments

Cyproterone (Androcur®) 50-100 mg PO BID or TID  
Megestrol (Megace®) 80-160 mg PO daily  
Ketoconazole (Nizoral®) 400 mg PO TID (+/- Hydrocortisone 20 mg qAM & 10 mg qPM)  
Estrogens- e.g. Diethylstilbestrol 1 mg PO Daily


## 8.6 Post-Prostatectomy Management



## 8.7 Salvage Therapy




## 8.8 Metastatic and Incurable Prostate Cancer




Consider referral to Palliative Care service (see page 29) and/or provincial home care service


## 8.9 Hormone Refractory Prostate Cancer




## 8.10 Management of Sexual Dysfunction




## 8.11 Management of Incontinence



## 8.12 Management of Psychosocial Issues



## 8.13 Management of Pain and Other Symptoms





1278 Tower Road  
5th floor Bethune Building  
Halifax, Nova Scotia B3H 2Y9

Phone: 902-473-4645  
Toll free: 1-866-599-2267  
Fax: 902-473-4631

Email: [info@ccns.nshealth.ca](mailto:info@ccns.nshealth.ca)  
[www.cancercare.ns.ca](http://www.cancercare.ns.ca)